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ABSTRACT
Objective: Ampicillin plus sulbactam, an irreversible [3-1actamase inhibitor, was compared to cefox-
itin in the treatment of women with acute pelvic inflammatory disease (PID) with and without
inflammatory mass(es).
Methods: Participation in an open, prospective, randomized clinical trial was offered to all women
given the clinical diagnosis of acute PID who required inpatient therapy. Neisseria gonorrhoeae and
Chlamydia trachomatis were sought in cervical and endometrial samples and aerobic and anaerobic
species were sought in endometrial samples prior to treatment initiation. Treatment was given on at
least 4 days and until women were afebrile for at least 48 h. Daily examinations were performed to
assess response to therapy and safety. Only women in whom C. trachomatis was identified were
discharged from the hospital on oral doxycycline to be taken for 10-14 days.
Results: One hundred twenty-four women were evaluated for safety; 117 (94%) were evaluated
for efficacy. Demographic characteristics were similar for women in each treatment group. N.
gonorrhoeae was recovered from 59% and C. trachomatis was recovered from 42% of study subjects.
Inflammatory masses were identified in 35/76 (46%) women given ampicillin/sulbactam and 17/41
(41%) women given cefoxitin. Ampicillin/sulbactam cured 75 of 76 women (98.7%) [95% confidence
interval (CI) 92.9-100.0%] and cefoxitin cured 37 of41 women (90.2%) (95% C176.9-97.3% in that
treatment regimen.
Conclusions: Overall ampicillin/sulbactam was more effective (P 0.05) than cefoxitin, due to
superior efficacy in infection complicated by inflammatory mass(es) 35/35 vs. 12/17 cured; P
0.007). (C) 1994 Wiley-Liss, Inc.
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variety of broad-spectrum single-agent and
combination regimens have been highly suc-
cessful when given to women hospitalized for treat-
ment of acute pelvic inflammatory disease (PID).
The optimal antibiotic regimen for inpatient ther-
apy of such women has not been established. The
etiology of this acute pelvic infection is generally
thought to involve Neisseria gonorrhoeae, Chlamy-
dia trachomatis, and a wide variety of anaerobic and
aerobic bacteria. Treatment regimens must include
broad-spectrum coverage of these likely pathogens.
Additionally, therapy must be effective in the vari-
ous forms and complications of PID (e.g., endo-
metritis, salpingitis, and pelvic inflammatory mass/
abscess). Combination antimicrobial therapy has
been recommended by the Centers for Disease Con-
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trol and Prevention (CDC) since 1982.1 However,
many single-agent therapeutic regimens, including
cefoxitin, have been successful in the treatment of
women with PID. 2’3 Ampicillin alone was shown
to be effective in one small clinical trial.
4 Since
many potentially significant pathogens of pelvic
infection produce ]3-1actamase enzyme, the addi-
tion ofa suicide-type [3-1actamase inhibitor to ampi-
cillin should enchance and extend its antibacterial
activity.
A prospective, randomized, open clinical trial
was designed in which women with clinical symp-
toms and signs of acute PID who required hospital-
ization for therapy would be treated with intrave-
nous (IV) ampicillin/sulbactam or cefoxitin. This
report details results of early (inpatient) therapy
only.
SUBJECTS AND METHODS
Women 18 years of age or older who presented to
the emergency room ofParkland Memorial Hospi-
tal complaining of lower abdominal and/or pelvic
pain and who had abdominal, cervical motion, uter-
ine, and adnexal tenderness were considered for
inclusion in this clinical trial. They also had to have
one or more of the following: temperature >38C;
leukocyte count >10,000/mm3; Gram-negative
diplococci in the endocervix; pelvic inflammatory
mass(es); or leukocytes and bacteria from a perito-
neal specimen. Pregnant or breastfeeding women
were excluded as were those who were suspected to
have a ruptured abscess; required concomitant anti-
microbial therapy; had a history of known hyper-
sensitivity reaction to cephalosporins, penicillin, or
tetracyclines; had received successful antibiotic ther-
apy within the 4 days preceding consideration for
study entry; were receiving another investigational
drug; had impaired immunological function and/or
leukopenia (< 1,500/mm); and had clinically sig-
nificant renal dysfunction. Women who met the
inclusion and exclusion criteria and who signed an
Institutional Review Board-approved consent form
were sequentially enrolled in this clinical trial.
Prior to antimicrobial administration, material
recovered from the endocervix with a sterile swab
was cultured for N. gonorrhoeae and tested for
C. trachomatis by culture and/or for fluorescent
antibody detection by MicroTrak(R) (Syva Com-
pany, San Jose, CA). An endometrial sample also
was obtained using a Pipelle(R) (Unimar, Wilton,
CT) for identification of N. gonorrhoeae, C. tra-
chomatis, and aerobic and anaerobic bacteria in the
departmental research microbiology laboratory. N.
gonorrhoeae specimens were plated directly onto
Martin-Lewis Transgrow(R) media (Remel, Len-
exa, KS) for identification using the quadFERM(R)
system (Analytab Products, Plainview, NY). C.
trachomatis specimens were placed into refrigerated
Multi-Microbe(R) medium (MicroTest, Inc., Snell-
ville, GA) for transport and cultured in McCoy(R)
cells (Ortho Diagnostic, Ranton, NJ). Identifica-
tion was made using the Syva(R) confirmation test
(Syva Company). Gram-negative aerobic isolates
were identified using the API 20-E(R) system
(Analytab Products) and conventional methods
were employed for identification of Gram-
positive aerobic bacteria. Anaerobic isolates were
processed in a Coy(R) anaerobic glove box (Coy
Laboratory Products, Ann Arbor, MI) on stan-
dard media and identified using the API 20-A(R)
system (Analytab Products). Agar dilution suscep-
tibility testing by minimal inhibitory concentration
was performed using National Committee for Clin-
ical Laboratory Standards (NCCLS) guidelines for
aerobic (MT-T2) and anaerobic (M1 I-A) bacteria.
Standard reference powder of each antibiotic was
provided by the manufacturer. [3-Lactamase was
detected using a nitrocephin disk (Becton-Dickin-
son, Cockeyville, MD).
The following clinical laboratory studies were
performed prior to the initiation of therapy, at the
completion of successful therapy, when therapy
failed, or when patients left the hospital against
medical advice (AMA): complete blood count
(CBC) with differential; hepatic and renal function
tests; direct Coombs test; prothrombin time (PT);
partial thromboplastin time (PTT); and urinalysis.
Women treated under this protocol were given
consecutive study numbers as they were enrolled,
and treatment was randomly assigned according to
a 2:1 (ampicillin/sulbactam:cefoxitin) computer-
generated randomization schedule. The regimen
doses for ampicillin/sulbactam and cefoxitin were 3
and 2 g, respectively. Each therapeutic regimen
was to be administered IV every 6 h on at least 4
consecutive days and until the patient was afebrile
for at least 48 h. Sonography was performed on all
study subjects to identify and document inflamma-
tory pelvic mass(es). Results were interpreted by
of 4 faculty sonographers using the criteria of a
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complex enlargement that was predominantly so-
nolucent and septated with irregular borders in the
region of an adnexa without an ovary detected sepa-
rately. Doppler flow imaging was not performed.
Women with C. trachomatis at study entry were
given 100-mg doxycycline tablets to be taken orally
twice daily for 10-14 days when discharged from
the hospital. Subjects negative for C. trachomatis
were discharged on no oral antibiotic.
The study subjects were evaluated clinically twice
daily during hospitalization. Clinical cure was de-
fined as resolution of abnormal tenderness, disap-
pearance of temperature elevation for at least 48 h,
normalization of the leukocyte count, and no re-
quirement for other antimicrobial or surgical ther-
apy for the original infection. It was necessary to
receive a regimen for at least 48 h to be evaluable
for efficacy. Clinical failure was defined as persis-
tent or increasing symptoms, physical findings, and
temperature after at least 48 h of" the original regi-
men necessitating alternative antimicrobial or sur-
gical therapy.
A power analysis indicated that 120 study sub-
jects (2:1 :ampicillin/sulbactam: cefoxitin) would be
required to have an 80% chance of detecting a
difference in efficacy of 20%, assuming an efficacy
of 95% for ampicillin with sulbactam. Data were
analyzed utilizing two-tailed Fisher’s exact, log like-
lihood X2, Welch’s approximation, and Student’s
t-tests. Exact confidence intervals (CI) were calcu-
lated. Clinical significance was defined as P <
0.05.
RESULTS
One hundred twenty-four women were entered into
this clinical trial over 37 months; 117 (94%) were
evaluable for clinical efficacy determination. Seven
women, given cefoxitin and 6 given ampicillin/
sulbactam, were exluded from clinical evaluation.
The woman given cefoxitin was treated for suba-
cute bacterial endocarditis. Three women given
ampicillin/sulbactam left the hospital AMA and 2
others were given additional antimicrobial treat-
ment for syphilis and Trichomonas vaginalis vagini-
tis prior to completion of protocol therapy. One
other study subject experienced recurrent pruritus
which began on her third day of ampicillin/
sulbactam therapy; she was clinically improving
and was treated for 2 more days with clindamycin
TABLE I. Demographic and contraception





Characteristic (N 76) (N 41)
Age (years) 24.0 -+ 4.7 24.5 +- 5.9
Height (in.) 64.0 +- 2.7 64.0 +- 3.2
Weight (Ib) 139. -+ 41.9 142.7 30.
Gravidity 1.2 +-1.4 I.I- 1.8
Parity 0.8 -+ I.I 0.9 -
1.8
Race
Black 58 (76) 31 (76)
Caucasian 10 (I 3) 7 (I 7)
Hispanic 8 (I I) 3 (7)
Contraception
None 51 (67) 32 (78)
Oral contraceptives (14) 6 (I 5)
Barrier 7 (9) (2)
Tubal ligation 5 (7) (2)
Intrauterine device 2 (3) (2)
Previous PID 14 (18) 9 (22)
Previous N. gonorrhoeae 25 (33) 10 (24)
Data are presented as mean standard deviation or number with per-
cent in parentheses.
and gentamicin. Study numbers for these subjects
were 5, 41, 44, 65, 86, 112, and 123.
Demographic, contraceptive, and prior infec-
tion variables for the evaluable women were statis-
ticall similar and are presented by therapeutic reg-
imen in Table 1. Infection-related variables (Table
2) were also similar, except for a higher mean
temperature reading at study entry in women given
ampicillin/sulbactam. Of the 52 women with in-
flammatory mass(es), 24 (46%) denied a history of
PID or positive culture for N. gonorrhoeae.
Excluding N. gonorrhoeae and C. trachomatb,
489 aerobic and anaerobic bacteria were recovered
from endometrial specimens obtained from these
117 evaluable women (Table 3). The predominant
aerobic endometrial isolates were Gram-positive or-
ganisms (86%); peptostreptococci accounted for
44% of anaerobic isolates. Prevotella bivius was the
most frequently isolated Gram-negative anaerobe,
accounting for 23% of all identified anaerobic iso-
lates. The median number of isolates per patient
was 5 organisms. One hundred fifteen isolates
(23%) produced [3-1actamase. [3-Lactamase produc-
tion was observed most frequently in enterobacteri-
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TABLE 2. Entry infection-related variables for II 7 women treated for acute PID
a
Ampicillin/sulbactam




Duration of pain (days) 3.9 _+ 4.7 4.0 -+ 4.
Interval to last menstrual period (days) 12.5 10. 16. -+ 18.7
Leukocyte count (x 103/ram3) 16.4 +_ 6.0 17.1 +_ 5.4
Hemoglobin (g %) 12.6 -+ 1.6 12.7 _+ 1.5
Temperature (C)* 38.5 _+ 0.7 38.2 -+ 0.8
Inflammatory mass(es) 35 (46) 17 (41)
<6 cm size 15 (43) 8 (47)
6-10 cm size 17 (49) 7 (41)
>10 cm size 3 (8) 2 (12)
Data are presented as mean -+ standard deviation or number with percent in parentheses.
*P 0.04.
TABLE 3. Endometrial isolates recovered prior to therapy of women with acute PID
No. of 13-Lactamase Ampicillin/




Neisseria gonorrhoeae 69 3 (4)
Chlamydia trachomatis 49
Staphylococcus epidermidis 78 13 (17)
Staphylococcus aureus 10 3 (30)
Streptococcus species 46 <0.25
Streptococcus agalactiae 27 <0.25
Enterococcus faecalis IS
Escherichia coli 21 9 (43) 32
Proteus species 2 0.5
Pseudomonas aeruginosa 2 <0.25
Klebsiella pneumoniae (100) 4
Citrobacter diversus <0.25
Acinetobacter calcoaceticus var. (100) 0.5
anitratus
Peptostreptococcus species 126 (I)
C,Iostridium species 4 0.5
Propionibacterium species II (9)
Prevotella/Bacteroides species 66 34 (52)
Prevotella bivius 51 33 (65) 2
Bacteroides fragilis
fragilis 6 6 (I 00) 4
distasonis 16
thetaiotaomicron 2 2 (100)
vulgatus 3 3 (100) 4
Prevotella disiens 7 3 (43) <0.25





















Data are presented as number or number with percent in parentheses.
bAntibiotic concentration in ig/ml inhibiting 90% of bacterial species.
Patients with recovery at endocervical and/or endometrial sites.
aceae and Prevotella or Bacteroides species. Only 3
gonococcal strains (4%) produced [3-1actamase.
The recovery of N. gonorrhoeae and C. Tracho-
matis from the endocervix and endometrium was
similar in both treatment regimens (data not
shown). Of the 117 evaluable women, 40 (34%)
had N. gonorrhoeae only, 20 (17%) had C. tracho-
mat# only, 29 women (25%) had both microorgan-
isms, and 28 women (24%) had neither of these
species. Of the 69 women (59%) with N. gonor-
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Success without mass 40/41 (97.6) 24/24 (100)
Days of therapy 4.4 0.9 4.3 -+ 0.6
Success with mass* 35/35 (100) 13/17 (76.5)
Days of therapy** 4.9 -+ I. 6.0 -+ 2.
Overall success** 75/76 (98.7) 37/41 (90.2)
95% CI 92.9-100.0 76.9-97.3
Days of therapy 4.6 -+ 1.0 5.0 -+ 1.6
Data are presented as mean --+ standard deviation or number of patients
cured/number of patients treated with percent in parentheses.
P 0.007.
**P- 0.05.
Cefoxitin failures were diagnosed after a mean du-
ration of therapy of 5 days (range 4-7 days) with a
mean temperature of 3 8.3C (range 3 8.1-38.5C)
at therapy alteration. The altered therapy (clin-
damycin, gentamicin, and ampicillin) was admin-
istered for a mean of4 days (range 3-6 days) before
discharge from the hospital..
Clinical and laboratory adverse events were not
clinically serious and were comparable for women
in each antibiotic treatment regimen (Table 5).
Only the previously mentioned women with an
allergic reaction to ampicillin/sulbactam had an ad-
verse reaction dictating removal from the study
protocol.
rhoeae, 61 (88%) had isolates recovered from both
cervical and endometrial sites, 6 (9%) had isolates
only in the cervix, and 2 (3%) had isolates recov-
ered only from endometrial specimens. The same
recovery rates by site for the 49 women (42%) with
C. trachomatis were 33 (68%), 9 (18%), and 7
(14%), respectively. N. gonorrhoeae was found in
both the cervix and endometrium ofinfected women
more frequently (_P 0.015) than was C. tracho-
mat#. The absence of N. gonorrhoeae and/or C.
trachomatis was associated with failure of the origi-
nal regimen (P 0.011).
Clinical outcome data for the study subjects are
presented in Table 4. The overall rate of cure was
higher for women treated with ampicillin/
sulbactam, due primarily to its efficacy in the treat-
ment of PID complicated by inflammatory
mass(es). All 5 women who failed initial therapy
required alteration in their therapy, which they
received for a mean duration of 9 days. All 4 of the
cefoxitin failures occurred in women with inflam-
matory masses of 6 cm or larger, and of the 4
women required abscess drainage by colpotomy.
Only of the 5 treatment failures had either N.
gonorrhoeae or C. trachomatis; she had both patho-
gens, an inflammatory mass larger than 6 cm, and
was in the cefoxitin group. The woman who ulti-
mately failed therapy with ampicillin/sulbactam had
therapy altered on day 6 of therapy. Her tempera-
ture was 3 8.3C, and she had moderate tenderness.
Her therapy was altered to clindamycin and gen-
tamicin, and she was discharged 3 days later. Her
admission leukocyte count was 38.3 103/mm3,
and it was 20.5 103/mm3 at therapy alteration.
DISCUSSION
According to data from the CDC through 1991,5
the reported number of women from whom N.
gonorrhoeae was recovered has been steadily decreas-
ing over the past 10 years in the United States. The
number ofwomen hospitalized for therapy of acute
PID has decreased even more markedly over the
same time period.
6 The explanation for these trends
in the United States is unclear, especially since rates
of syphilis have increased during the same period.
7
N. gonorrhoeae continues to be the sexually trans-
mitted disease species most frequently recovered
from women admitted to our hospital for parenteral
therapy. Although the percentage ofwomen admit-
ted for inpatient therapy who had N. gonorrhoeae
has remained relatively constant at between 50 and
60% over the past 7 years (data not shown), the
number of women admitted has decreased almost
70% from 226 in 1985 to only 60 in 1992.
We found that the broad-spectrum antimicro-
bial regimen of ampicillin/sulbactam given 3g IV
every 6 h was clinically superior to cefoxitin 2 g IV
every 6 h in the treatment of women with acute
PID diagnosed in an emergency room. On sub-
group analyses, the efficacy of the 2 regimens was
similar for uncomplicated PID. However, in
women with infection complicated by pelvic in-
flammatory mass(es) detected by physical and ultra-
sound examinations, ampicillin/sulbactam had sig-
nificantly greater efficacy. Furthermore, in this
latter group the mean number of days of therapy
for women treated with ampicillin/sulbactam was
less than that ofwomen treated with cefoxitin, sug-
gesting a more rapid therapeutic response.
Not unexpectedly, the treatment failures were
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TABLE S. Adverse events in 124 women treated as inpatients for acute PID
a
Ampicillin/Sulbactam





Diarrhea 3 (4) 4 (10)
Pruritus 2 (2) 2 (5)
IV site pain/edema 2 (2) 0 (0)
IV site phlebitis (I) (2)
Rash 0 (0) ()
Laboratory test
Aspartate aminotransferase 3 (4) 3 (7)
Alkaline phosphatase 3 (4) (2)
PTT () (2)
Data are presented as number with percent in parentheses.
Elevation out of normal range at end of therapy with normal value prior to study entry.
generally associated with non-gonococcal, non-
chlamydial infection and large (>6 cm) pelvic in-
flammatory masses at enrollment. Almost half of
these women denied previous pelvic infection, in-
dicating that inflammatory mass formation can com-
plicate an initial infection. All of the cefoxitin-
treated failures were women with pelvic masses. In
this protocol, we followed our usual practice of
clinically following all women after treatment for
PID, especially to detect resolution or persistence
of inflammatory mass(es). In a previous clinical
trial,
1 only 12% of women had a persistent ad-
nexal mass that required surgical diagnosis/therapy.
A sterile hydrosalpinx was found in each instance.
Neither of the regimens presented here is rec-
ommended for adequate treatment of C. trachomatis
infection. Previous investigators have confirmed
that 13-1actam antimicrobial agents have clinical ef-
ficacy in acute PID, but may fail to eradicate C.
trachomatis. 8’9 Clinical success of initial regimens
not active against chlamydia has been observed in
patients treated in our hospital under prospective
protocols.
1-13 If the addition of doxycycline to
PID regimens is only to eradicate C. trachomat#, it
seems appropriate to identify those women and pro-
vide specific therapy. If testing is not done, all
women should be treated. Administration of doxy-
cycline for acute PID did not prevent adhesion
formation or tubal occlusion in a report by Teisala
and coworkers.
14 In that report, women with C.
trachomatis prior to treatment with penicillin and
metronidazole did not have it when retested at sec-
ond-look laparoscopy. According to Westrom and
coinvestigators,
is tetracycline treatment did not re-
sult in a significantly lower incidence of post-infec-
tion tubal occlusion in an earlier report on a large
number of Scandinavian women treated for PID.
All women in both treatment regimens were given
oral doxycycline at hospital discharge if they had
chlamydia at enrollment into the clinical trial. Ex-
perimental polymerase chain reaction (PCR)-based
testing appears to be more sensitive and specific
than currently available techniques, including cul-
ture. When developed and available, it may pro-
vide the most exact means of identifying C. tra-
chomatis in clinical settings.
There are several limitations to this study. All
diagnoses were clinical and not laparoscopic. In
1969 Jacobson and Westrom
16 reported that an
accurate clinical diagnosis of acute PID was made
in only 65% of women undergoing laparoscopy.
Hadgu and coworkers
17 reported that, if women
were young, unmarried, had vaginal discharge,
fever, tender adnexal swelling, an elevated erythro-
cyte sedimentation rate, and N. gonorrhoeae in the
cervix, the probability of the accuracy of the clini-
cal diagnosis was 97%. Cumming et al.
18 sug-
gested that normal laparoscopic findings did not
exclude significant endosalpingeal infection, and
Sellors and colleagues
19 reported that laparoscopic
visualization of the fallopian tube was 50% sensi-
tive with 80% specificity for the diagnosis of sal-
pingitis when fimbrial histopathology was utilized
to establish the diagnosis. In our opinion, data do
not support routinely performing laparoscopy in all
women given the clinical diagnosis of PID using
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criteria proposed by Hager and coworkers,
2 which
were utilized in this clinical trial.
Follow-up endocervical and endometrial cultures
were only performed for clinical treatmentfailures.
Thus, the relation between bacteriologic and clini-
cal cure was not examined. This report does not
address long-term clinical response and fertility,
both important components in long-term efficacy
analyses. The potential for biased selection for en-
try did exist since this was an open clinical trial. All
women given the diagnosis of acute PID who re-
quired inpatient therapy and met inclusion/
exclusion criteria were approached for participation
and consent. The 2 study groups were similar in
terms of demography, clinical presentation, micro-
biologic spectrum of pelvic pathogens, and the fre-
quency and relative sizes of inflammatory mass(es)
were similar in both sets of patients. Thus, there
appeared to be no selection biases in the hospital-
ized treatment groups.
In summary, we conclude that ampicillin/
sulbactam was significantly more effective than
cefoxitin for the inpatient treatment of" acute PID,
especially when complicated by pelvic inflamma-
tory mass(es).
ACKNOWLEDGMENTS
This work was supported in part by a Grant-in-Aid
from Roerig Pharmaceuticals.
REFERENCES
1. Centers for Disease Control: Sexually transmitted diseases
treatment guidelines 1982. Morbidity and Mortality
Weekly Report 3 l(Suppl 2):33S-60S, 1982.
2. Peterson HB, Walker CK, Kahn JG, Washington AE,
Eschenbach DA, Faro S: Pelvic inflammatory disease.
Key treatment issues and options.JAMA 266:2605-2611,
1991.
3. Peterson HB, Galaid EI, Zenilman JM: Pelvic inflam-
matory disease: Review of treatment options. Rev Infect
Dis 12(Suppl 6): $656-$664, 1990.
4. Spence MR, Genadry R, Raffel L: Randomized prospec-
tive comparison ofampicillin and doxycycline in the treat-
ment of acute pelvic inflammatory disease in hospitalized
patients. Sex Transm Dis 8(Suppl 2):164-166, 1981.
5. Centers for Disease Control: Summary of notifiable dis-
eases, United States, 1991. Morbidity and Mortality
Weekly Report 40:24, 1991.
6. Centers for Disease Control: Pelvic inflammatory disease:
Guidelines for prevention and management. Morbidity
and Mortality Weekly Report 40:4, 1991.
7. Gersham KA, Rolls RT: Diverging gonorrhea and syph-
ilis trends in the 1980’s: Are they real? Am J Public
Health 81:1263-1266, 1991.
8. Sweet RL, Schachter J, Robbie MO: Failure of 13-1actam
antibiotics to eradicate Chlamydia trachomatis in the en-
dometrium despite apparent clinical cure of acute salpin-
gitis. JAMA 250:2641-2645, 1983.
9. Kousseim M, Ronald A, Plummer FA, D’Costa L, Brun-
ham RC: Treatment of acute pelvic inflammatory disease
in the ambulatory setting: Trial of cefoxitin and doxycy-
cline versus ampicillin-sulbactam. Antimicrob Agents
Chemother 35:1651-1656, 1991.
10. Hemsell DL, Santos-Ramos R, Cunningham FG, No-
bles BJ, Hemsell PG: Cefotaxime treatment for women
with community acquired pelvic abscesses. Am J Obstet
Gynecol 151:771-777, 1985.
11. Hemsell DL, Hemsell PG, Heard ML, Nobles BJ: Pip-
eracillin and a combination of clindamycin and gentami-
cin for hospital and community acquired acute pelvic
infections including pelvic abscess. Surg Gynecol Obstet
165:223-229, 1987.
12. Hemsell DL, Nobles BJ, Heard MC, Hemsell PG: Up-
per and lower reproductive tract bacteria in 126 women
with acute pelvic inflammatory disease: Microbial suscep-
tibility and clinical response to four therapeutic regimens.
J Reprod Med 33:799-805, 1988.
13. Hemsell DL, Wendel GD, Gall SA, Newton ER, Gibbs
RS, Knuppel RA, Lane TW, Sweet RL: Multicenter
comparison of cefotetan and cefoxitin in the treatment of
acute obstetric and gynecologic infections. Am J Obstet
Gynecol 158:722-728, 1988.
14. Teisala K, Heinonen PK, Aine R, Punnonen R, Paa-
vonen S: Second look laparoscopy after treatment of acute
pelvic inflammatory disease. Obstet Gyneco169:343-346,
1987.
15. Westrom L, Iosif S, Svensson L, Mirdh P-A: Infertility
after acute salpingitis: Results of treatment with different
antibiotics. Curr Ther Res 26:752-759, 1979.
16. Jacobson L, Westrom L: Objectivized diagnosis of acute
pelvic inflammatory disease. Diagnostic and prognostic
values of routine laparoscopy. Am J Obstet Gynecol 105:
1088-1098, 1969.
17. Hadgu A, Westrom L, Brooks CA, Reynolds GH,
Thompson SE: Predicting acute pelvic inflammatory dis-
ease: A multivariate analysis. Am J Obstet Gynecol 155:
954-960, 1986.
18. Cumming DC, Honor6 LH, Scott JZ, Williams KE:
Microscopic evidence of silent inflammation in grossly
normal fallopian tubes with ectopic pregnancy. Int J Fer-
til 33:324-328, 1988.
19. Sellors J, Mahony J, Goldsmith C, et al.: The accuracy
of clinical findings and laparoscopy in pelvic inflam-
matory disease. Am J Obstet Gynecol 164:113-120,
1991.
20. Hager WD, Eschenbach DA, Spence MR, Sweet RL:
Criteria for diagnosis and grading of salpingitis. Obstet
Gynecol 61 113-114, 1983.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 129